Decitabine (Dacogen®), a hypomethylating agent, is FDA-approved for treatment of patients (pts) with all FAB subtypes of MDS. The approved regimen of 15 mg/m2 intravenously (IV) over 3 hours (hrs) every (q) 8 hrs for 3 days repeating q 6 wks demonstrated an overall improvement rate (CR+PR+HI) of 30% in MDS pts. An alternative regimen, in which decitabine is administered 20 mg/m2 IV over 1 hr once daily for 5 consecutive days repeating q 4 wks not only permits outpatient therapy, but also showed promising efficacy in a pilot study (
Disclosure:Employment: Julie Larsen & Michael Cullen--MGI Pharma. Consultancy: Lucy Godley - serves on Dacogen External medical Communications Advisory Panel. Ownership Interests: Michael Cullen - CNS Response; Lucy Godley - stock options in L2 Biometrics, a startup company.; Michael Cullen - MGI Pharma. Research Funding: Hagop Kantarjian - MGI Pharma. Membership Information: Michael Cullen--CNS Response; Maria Baer--Speaker’s Bureau; Lucy Godley--Advisor for L2 Biometrics. Off Label Use: Alternate dosing schedule.